ABG
JSPR icon

Ally Bridge Group’s Jasper Therapeutics JSPR Stock Holding History

Ally Bridge Group’s Portfolio JSPR Stock Details JSPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-122,424
Closed -$2.62M – 31
2024
Q4 		$2.62M Sell
122,424
-277,042
-69% -$5.77M 2.24% 18
2024
Q3 		$7.51M Buy
399,466
+180,852
+83% +$3.6M 4.02% 9
2024
Q2 		$4.96M Sell
218,614
-71,329
-25% -$1.71M 2.96% 18
2024
Q1 		$8.51M Sell
289,943
-75,983
-21% -$1.35M 4.73% 11
2023
Q4 		$28.9M Buy
365,926
+51,510
+16% +$346K 17.2% 1
2023
Q3 		$2.2M Buy
314,416
+62,693
+25% +$765K 2.58% 13
2023
Q2 		$3.45M Hold
251,723
– – 4.18% 12
2023
Q1 		$4.56M Buy
+251,723
New +$4.65M 5.97% 9

Other funds holding JSPR

SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
QUSVM
Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Ally Bridge Group's JSPR Position: Q1 2025 in Review

Ally Bridge Group sold out of Jasper Therapeutics (JSPR) in Q1 2025, closing a stake of 122,424 shares — an estimated $2.62M sold.

Ally Bridge Group first reported a position in JSPR in Q1 2023 and held it in 8 quarters. The position peaked at $28.9M in Q4 2023. 68 funds tracked by Wall St. Rank hold JSPR as of Q1 2025.

  • Ally Bridge Group reported no remaining Jasper Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Ally Bridge Group sold 122,424 Jasper Therapeutics shares in Q1 2025, an estimated $2.62M.
  • Ally Bridge Group first reported a position in Jasper Therapeutics in Q1 2023 and held it in 8 quarters.
  • Ally Bridge Group's Jasper Therapeutics position peaked at $28.9M in Q4 2023.
  • 68 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q1 2025.

Based on Ally Bridge Group's 13F filing for Q1 2025, filed 15 May 2025.